Home/Pipeline/HSK29116

HSK29116

B-cell Malignancies

Phase I/IIActive

Key Facts

Indication

B-cell Malignancies

Phase

Phase I/II

Status

Active

Company

Haisco Pharmaceutical Group

About Haisco Pharmaceutical Group

Haisco Pharmaceutical Group's mission is to develop and deliver innovative, high-quality medicines to address unmet medical needs in China and globally. The company has achieved significant scale, becoming one of China's top pharmaceutical firms by market value, through a successful 'generic-to-innovative' transition strategy. Its core strategy is built on vertical integration, using stable cash flows from its generics and established drug portfolio to fund R&D in high-growth therapeutic areas, while expanding its commercial reach across China's vast healthcare market.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Respiratory Metabolic Central Nervous System

Other B-cell Malignancies Drugs

Drug	Company	Phase	Status
BAFFR Allo CAR-NK Cells	PeproMene Bio	Pre-clinical	Active
IKS03	Iksuda Therapeutics	Clinical	Active
TNB-486	Ancora Bio	Phase 1	Active
docirbrutinib (AS-1763)	Carna Biosciences	Phase 1b	Active
Abivertinib	Sorrento Therapeutics	Phase 1/2	Active
Kymriah® (tisagenlecleucel)	Novartis	Approved	Active
KITE-363	Gilead Sciences	Phase 1/2	Active
TG-1701	TG Therapeutics	Phase 1	Active
TG-1801	TG Therapeutics	Phase 1	Active
REC-3565	Recursion Pharmaceuticals	Phase 1	Active
Plamotamab (XmAb®13676)	Xencor	Phase 2	Active (Partnered)
CAB-CD19 x CD3 T-cell Engager	BioAtla	Preclinical	IND-enabling